Current and prospective antibody-based therapies in multiple myeloma

Emily Bryer, Christin DeStefano*, Dickran Kazandjian*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalSeminars in Oncology
Issue number1
StatePublished - Feb 2022
Externally publishedYes


  • Belantamab
  • BiTE
  • Daratumumab
  • Elotuzumab
  • Immunoconjugates
  • Isatuximab
  • Monoclonal antibody
  • Multiple myeloma


Dive into the research topics of 'Current and prospective antibody-based therapies in multiple myeloma'. Together they form a unique fingerprint.

Cite this